Why Underwriting Evidence Ages Too Quickly for Reinsurers to Trust

The Underwriting Evidence That Looked Fine at Issue and Wrong Six Months Later

Every underwriting decision in life and health reinsurance rests on evidence gathered at a single moment in time. A lab panel, an attending physician statement, a BMI reading, a prescription history pull.

That evidence is treated as if it describes the applicant for the life of the treaty. In reality, it often stops being accurate within months, sometimes before the policy is even issued.

This is not a data-quality complaint about sloppy underwriting. It is a structural mismatch between how fast an applicant's health can change and how long a reinsurer keeps pricing off the evidence collected at a single point in time.

What Does It Mean for Evidence to Age Too Quickly?

Evidence ages too quickly when it stops accurately describing the applicant well before the reinsurer stops relying on it.

A lab result, an exam finding, or a BMI reading is a snapshot. It is accurate for the day it was taken, and its accuracy decays from there at a rate that depends entirely on what it is measuring.

Blood pressure can move within weeks. Weight can move within months, especially with certain treatments. Chronic disease status can move within a year or more.

The problem is that underwriting and pricing treat all of these the same way, as if the snapshot holds for the full duration of the risk being priced. It does not, and the gap between snapshot and reality is exactly where reinsurance risk quietly accumulates.

Why Is Speed a Different Problem From Recency?

Faster issuance and fresher evidence solve two different problems, and confusing them is where most of the exposure hides.

RGA's research on accelerated underwriting is explicit about the goal: carriers want "to reduce the need for the in-person medical exams and lab tests used in traditional underwriting, thus accelerating the process of policy issuance." That is a speed goal, measured in days saved.

Recency is a separate axis entirely. The same research notes that even with faster data sources, "obtaining the exact same information with adequate recency remains a challenge."

A reinsurer can have a five-minute issuance process built entirely on evidence that is itself months old by the time it gets pulled. Speed improved, and the underlying recency problem did not move at all.

Why Do Carriers Prioritize Speed Over Recency?

Carriers prioritize speed because it is directly tied to sales conversion, while recency is a harder cost to see.

Among carriers surveyed on accelerated underwriting goals, reducing time to issue was cited most often, at 52 percent, ahead of managing mortality slippage at 45 percent and increasing sales at 41 percent. Speed has an obvious, immediate business case.

Recency does not show up on a dashboard the same way. It shows up years later, in claims experience that quietly diverges from what the evidence at issue implied, which is exactly the kind of delayed signal a reinsurer's actuarial team should be watching for.

What Is the Sharpest Current Example of This Problem?

GLP-1 medications are the clearest live case of evidence aging inside the policy period itself, not just before issuance.

These drugs can produce large, fast changes in weight and BMI within months of starting treatment. A BMI reading taken at underwriting can already be out of date by the time the policy is bound.

RGA's research on this class of drugs puts it directly: "insurers will need to consider an applicant's BMI history rather than simply BMI at the time of application." A single number at one point in time was never designed to capture a trajectory like this.

The reverse case matters just as much. If treatment stops, RGA notes "the weight gain that occurs if treatment is stopped may be dramatic," with "concomitant increases in mortality and morbidity risk throughout the duration of the policy."

That risk reappears mid-treaty, with no natural point at which pricing gets to catch up. This is the same dynamic explored from the pricing-impact angle in what it actually costs to carry stale evidence into the next renewal.

Does Alternative Data Actually Solve the Recency Gap?

No, alternative data sources shift where the recency problem sits rather than eliminating it.

Prescription drug histories are "now regularly used in underwriting," and clinical lab and medical claims data show increased use as well, according to RGA's research. These sources are genuinely useful and often fresher than a scheduled exam.

But they are not complete substitutes. Regular clinical check-ups may "lack test results common in traditional full underwriting," including markers like HIV, cotinine, and kidney or liver function.

Even something as basic as height and weight is inconsistent in structured alternative data. RGA notes that "basic height and weight data may not be commonly found in structured alternative data sources," which means the exact input most sensitive to fast change is sometimes the hardest one to refresh reliably.

How Does This Look at Portfolio Scale, Not Just One Policy?

At portfolio scale, evidence aging stops looking like individual underwriting noise and starts looking like a systematic pricing gap.

One policy with slightly outdated evidence is immaterial. A book of thousands of policies underwritten on the same evidence-recency standard, or lack of one, is a different problem entirely.

A reinsurer assuming risk across many cedants inherits whatever evidence-recency practice each cedant happens to run. Some will refresh aggressively, some will not, and none of that variation is visible in a treaty submission unless it is specifically asked for.

That is precisely the kind of blended, cross-cedant exposure a reinsurer is positioned to see before any single primary insurer can, provided someone is actually looking for it. The related question of who owns that lookout inside a reinsurer's own organization is covered in the decision rights needed to control this exposure.

Why Does This Matter More for Long-Duration Treaties?

Long-duration treaties carry evidence-aging risk for the full life of the business, with no natural point to correct it.

A one-year renewable term treaty gets a fresh look at pricing every year, which limits how far a stale-evidence problem can travel before it gets caught. A twenty or thirty-year life treaty has no such checkpoint.

Whatever evidence-recency gap existed at issue is locked in for the duration. If that gap systematically favors the applicant, meaning the true risk is worse than the evidence suggested, the reinsurer carries that mispricing for decades, not months.

This is exactly why evidence-recency standards deserve the same scrutiny reinsurers already apply to mortality improvement assumptions and other long-duration pricing inputs. Both are cases where a number that looked settled at underwriting quietly stops matching reality well before the treaty runs its course.

What Should a Reinsurer Actually Do About This?

A reinsurer should treat evidence recency as an explicit, measured underwriting standard, not an informal byproduct of exam scheduling.

That starts with asking cedants a direct question during due diligence: how long is evidence considered valid before it must be refreshed, broken down by evidence type rather than treated as one blanket rule. Most cedants will not have a crisp answer unless they have already been asked.

Tools built for this exact gap help close it in practice. A cedant using a Medical Record Summarization AI Agent or a Prescription History Analysis AI Agent can surface evidence age automatically at the point of underwriting, rather than leaving it to manual file review.

That visibility is the first step toward the kind of workflow fix covered in more operational depth in how better workflow design reduces this exposure. Without it, a reinsurer is pricing risk it cannot actually see the age of.

How Does This Interact With Non-Disclosure and Claims Contestability Rules?

Stale evidence complicates claims contestability because it blurs the line between what an applicant failed to disclose and what simply changed after underwriting closed.

Contestability provisions exist to protect insurers and reinsurers against material misrepresentation at the time of application. They were not designed to handle a case where the applicant disclosed accurately, and the evidence itself was accurate at the time, but the underlying condition moved on before the contestability period even began.

That distinction matters enormously at claims time. A claims examiner reviewing a death or disability claim years after issuance needs to know whether a gap between file evidence and actual health reflects misrepresentation or simply evidence aging, because the two lead to very different claims outcomes and very different legal exposure.

Reinsurers that have not built evidence-age tracking into the underwriting file are handing claims teams an impossible task years later, asking them to reconstruct a distinction the original file never captured. This is the same evidentiary gap explored from a claims-defensibility angle in claim defensibility and the elements behind large-scale repudiations, where the underlying lesson is the same: a file that cannot show its own evidence timeline is a weaker file at claims time, regardless of how accurate the original underwriting decision actually was.

How Should This Shape Due Diligence on a New Cedant Relationship?

Evidence-recency practice should be a scored, standard part of due diligence before a reinsurer commits capacity to a new cedant relationship.

Most due diligence reviews already cover underwriting guidelines, mortality experience, and claims handling practice in detail. Evidence-recency standards deserve the same level of specific scrutiny, not a passing mention buried inside a broader underwriting guidelines review.

A practical due diligence question set should ask for the cedant's evidence-type-specific refresh thresholds, how those thresholds are enforced in the underwriting system, and what percentage of a sample file set currently falls outside those thresholds. A cedant that can answer all three concretely is a materially different risk than one that can only offer a general assurance that its underwriting is sound.

This detail belongs in the treaty submission package itself, not just the informal underwriting conversation that happens before terms are finalized. Building it into the standard due diligence checklist is a low-cost change that meaningfully improves what a reinsurer actually knows before capacity gets committed.

Underwriting evidence was never meant to be a permanent description of an applicant, it was meant to be a starting point. Treating it as permanent is what turns a manageable, individually small gap into a portfolio-wide pricing problem that shows up years after the underwriting file was closed.

The reinsurers that get ahead of this are the ones asking cedants about evidence age today, not the ones waiting to see it show up in claims experience five years from now.

Sources

• RGA: Accelerated Underwriting: Maximizing its Future
• RGA: RGA GLP-1 Study: Weighing the Evidence